Cigna Corporation

🇺🇸New York Stock Exchange
Back to all articles
Cigna Corporation stock analysis CI overview
Somewhat Bullish +50

Here's Why Investors Should Hold On to Cigna Stock for Now

📈 Cigna Group (CI) has gained 7.2% year-to-date, though it underperforms the industry average of 20.1%.

💰 The stock trades at a forward P/E ratio of 9.35x, which is significantly lower than the industry average of 17.72x.

📊 Zacks Investment Research assigns Cigna a Rank #3 (Hold) with a Value Score of A based on its financial metrics.

🔮 Analysts project 2026 earnings of $30.38 per share, representing a 1.8% year-over-year increase.

💵 Consensus revenue estimates for 2026 stand at $287.5 billion, implying 4.7% growth compared to the prior year.

🏆 Cigna has beaten earnings estimates in each of the trailing four quarters with an average surprise of 1.9%.

📈 First-quarter 2026 adjusted income from operations rose 12% year-over-year driven by Healthcare and Evernorth segments.

💊 Evernorth Health Services expects adjusted operating income to reach at least $6.9 billion in 2026 on a pre-tax basis.

🏥 Cigna Healthcare is expected to generate a minimum of $4.5 billion in adjusted operating income for 2026.

📉 Adjusted SG&A expense ratio improved to 4.8% in the reported quarter from 5.8% a year ago.

💊 Evernorth introduced a new pharmacy benefits model that passes manufacturer discounts directly to customers starting in 2027.

🔄 Management approved a 3.3% increase in the quarterly dividend to $1.56 per share in February 2026.

📉 The company repurchased nearly 11.9 million shares for approximately $3.6 billion during 2025.

⚠️ Total benefits and expenses escalated by 4% in Q1 2026 following increases of 12% in 2025 and 4% in 2024.

💸 Long-term debt stands at $29.4 billion, which is significantly higher than the cash balance of $7 billion.

📉 The long-term debt to total capital ratio is 40.9%, slightly above the industry average of 40.5%.

🔍 Zacks suggests investors consider other medical stocks like BrightSpring Health (BTSG), Globus Medical (GMED), and Centene (CNC).

Bullish Signals
  • Cigna Group (CI) is well poised for growth driven by strong segmental performance, improving operating efficiency, and shareholder-friendly moves.
  • The company's shares have gained 7.2% year to date, indicating positive investor sentiment despite underperforming the industry average.
  • Cigna holds a Value Score of A and trades at a forward P/E ratio of 9.35x, which is significantly lower than the industry average of 17.72x, suggesting an attractive valuation.
  • Over the past month, earnings estimates have witnessed seven upward revisions against only one downward revision, signaling growing analyst confidence.
  • Cigna beat earnings estimates in each of the trailing four quarters with an average surprise of 1.9%, demonstrating consistent execution.
  • First-quarter 2026 adjusted income from operations rose 12% year over year, driven by strong growth in Cigna Healthcare and Evernorth Health Services.
  • The company expects Evernorth Health Services' adjusted operating income to reach at least $6.9 billion in 2026, while Cigna Healthcare is expected to generate a minimum of $4.5 billion.
  • Cigna's first-quarter 2026 adjusted revenues increased 4.7% year over year to $68.5 billion, reflecting solid top-line growth.
  • The adjusted SG&A expense ratio improved to 4.8% in the reported quarter from 5.8% a year ago, highlighting enhanced operating efficiency.
  • Evernorth Health Services introduced a transformative pharmacy benefits model that passes drug manufacturer discounts directly to customers, lowering out-of-pocket costs and potentially driving volume.
  • Cigna continues to demonstrate a strong commitment to enhancing shareholder value through significant capital returns.
  • The company repurchased nearly 11.9 million shares for approximately $3.6 billion in 2025, showing confidence in its stock price.
  • Management approved a 3.3% increase in the quarterly dividend in February 2026, raising it to $1.56 per share with a current yield of 2.12%, which is higher than the industry average of 1.94%.
Risk Factors
  • Cigna's stock has underperformed the industry average, gaining only 7.2% year to date compared to an industry increase of 20.1%.
  • Total benefits and expenses escalated significantly with a 12% year-over-year increase in 2025 and another 4% rise in the first quarter of 2026, which might weigh on margin growth.
  • Pharmacy and other service costs increased 12% year over year due to changes in claims composition, creating pressure on profitability.
  • Cigna carries a significant debt level with long-term debt of $29.4 billion at the end of the first quarter of 2026, which is significantly higher than its cash balance of $7 billion.
  • The company's long-term debt to total capital ratio of 40.9% is slightly above the industry average of 40.5%, likely keeping pressure on interest expenses going forward.
Full Analysis
Cigna Group (CI) is positioned for growth driven by strong segmental performance, improved operating efficiency, and shareholder-friendly initiatives. The company's shares have gained 7.2% year to date, underperforming the industry average of 20.1%, though its forward P/E ratio of 9.35x remains lower than the industry average of 17.72x, indicating an attractive valuation. Cigna holds a Zacks Rank #3 (Hold) and a Value Score of A, with consensus estimates pegging 2026 earnings at $30.38 per share, representing a 1.8% year-over-year increase, and revenues at $287.5 billion, indicating 4.7% growth. The company beat earnings estimates in each of the trailing four quarters with an average surprise of 1.9%. In the first quarter of 2026, adjusted income from operations rose 12% year over year, driven by growth in Cigna Healthcare and Evernorth Health Services. The company expects Evernorth's adjusted operating income to reach at least $6.9 billion in 2026, while Cigna Healthcare is expected to generate a minimum of $4.5 billion. Adjusted revenues increased 4.7% year over year to $68.5 billion in the reported quarter. Positive factors include business mix shifts and improved operating efficiency, with the adjusted SG&A expense ratio improving to 4.8% from 5.8% a year ago. Evernorth Health Services introduced a transformative pharmacy benefits model that passes drug manufacturer discounts directly to customers, lowering out-of-pocket costs. Cigna plans to adopt this model for fully insured customers starting in 2027 and is raising its 2026 profits outlook for the Cigna Healthcare segment. The company also demonstrates a strong commitment to enhancing shareholder value, having repurchased nearly 11.9 million shares for approximately $3.6 billion in 2025 and approved a 3.3% increase in the quarterly dividend in February 2026, raising it to $1.56 per share with a current yield of 2.12%. However, investors should monitor escalating total benefits and expenses due to higher pharmacy and service costs, which increased 4% in 2024, 12% in 2025, and 4% in the first quarter of 2026. Pharmacy and other service costs increased 12% year over year, reflecting changes in claims composition, which might weigh on margin growth. Additionally, Cigna has a significant debt level with long-term debt of $29.4 billion at the end of the first quarter of 2026, significantly higher than its cash balance of $7 billion. Its long-term debt to total capital ratio of 40.9% is slightly above the industry average of 40.5%, likely keeping pressure on interest expenses going forward.